CARsgen Therapeutics Holdings Limited
HKEX:2171.HK
4.65 (HKD) • At close November 5, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | CARsgen Therapeutics Holdings Limited |
Symbool | 2171.HK |
Munteenheid | HKD |
Prijs | 4.79 |
Beurswaarde | 2,737,676,600 |
Dividendpercentage | 0% |
52-weken bereik | 2.48 - 11.88 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Zonghai Li M.D., Ph.D. |
Website | https://www.carsgen.com |
An error occurred while fetching data.
Over CARsgen Therapeutics Holdings Limited
CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product candidate that is in
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (HKD)
Cijfers zijn in miljoenen (HKD)